Skip to main content
. 2020 Oct 5;8(2):e000889. doi: 10.1136/jitc-2020-000889

Figure 1.

Figure 1

COXi use is associated with improved time-to-progression. Kaplan-Meier curves for time-to-progression in metastatic patients stratified by COXi use during first-course of ICI after diagnosis of metastatic disease for (A) melanoma cohort (n=90); (B) modified metastatic melanoma cohort (n=69) after Response Evaluation Criteria in Solid Tumors assessment; and (C) non-small cell lung cancer cohort (n=37). COXi, cyclo-oxygenase inhibitors; ICI, immune checkpoint inhibitor.